|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 9,855,335: Scope, Claims, and Patent Landscape
Summary
United States Patent 9,855,335, titled "Method of treating autoimmune diseases", was granted on January 30, 2018, and assigned to Regeneron Pharmaceuticals, Inc. This patent primarily covers specific monoclonal antibodies targeting cytokines involved in autoimmune pathologies, notably targeting IL-17A. The patent delineates a broad scope of antibody compositions, methods of treatment, and diagnostic applications, positioning itself as a critical patent in the autoimmune biologics landscape.
This analysis provides a detailed examination of the patent’s claims, scope, and positioning within the patent landscape, highlighting its strategic implications for the biopharmaceutical industry and research entities.
1. Patent Overview
| Patent Number |
US 9,855,335 |
| Filing Date |
June 13, 2014 |
| Issue Date |
January 30, 2018 |
| Assignee |
Regeneron Pharmaceuticals, Inc. |
| Technology Area |
Biologic therapeutics, autoimmune diseases, monoclonal antibodies |
Abstract Summary:
The patent claims monoclonal antibodies that selectively bind to IL-17A, with applications in treating autoimmune diseases such as psoriasis, psoriatic arthritis, and Crohn’s disease, among others. It also encompasses methods of producing the antibodies, pharmaceutical compositions, and methods of using these antibodies for therapeutic purposes.
2. Scope of the Patent Claims
2.1. Claim Structure Overview
The patent contains 35 claims divided mainly into:
- Independent Claims (1, 14, 27): Broadly covering monoclonal antibodies and their compositions.
- Dependent Claims: Detailing specific embodiments, modifications, or methods of use.
2.2. Core Independent Claims
| Claim No. |
Claim Focus |
Key Elements |
| Claim 1 |
Monoclonal antibody |
A monoclonal antibody that specifically binds human IL-17A with an affinity ≤ 1 nM, exhibiting cytokine neutralization activity. It encompasses both amino acid sequences and variants that maintain binding specificity. |
| Claim 14 |
Composition |
A pharmaceutical composition comprising the antibody of Claim 1 and a pharmaceutically acceptable carrier. |
| Claim 27 |
Method of treatment |
A method of treating an autoimmune disease in a human patient by administering an effective amount of the antibody of Claim 1. |
2.3. Specificity of Claims
The claims focus primarily on:
- Binding affinity: Sub-nanomolar to nanomolar affinity for IL-17A.
- Binding specificity: Does not bind to IL-17F or IL-17A/F heterodimer unless explicitly stated.
- Antibody formats: Immunoglobulin G (IgG) classes, with possible variants.
- Isotype descriptions: IgG1, IgG2, etc., with specific engineering features.
- Disease indications: Primarily targeting psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease.
2.4. Claim Evolution and Variants
Dependent claims incorporate:
- Specific amino acid sequences (e.g., complementarity-determining regions—CDRs).
- Mutations or modifications that preserve binding.
- Antibody fragments, including F(ab')₂ and Fab.
- Methods of manufacturing and formulation.
3. Patent Scope and Boundaries
| Scope Aspect |
Description |
| Broadness |
Encompasses monoclonal antibodies with defined binding properties to IL-17A, covering sequence variants retaining functional activity. The patent effectively shields a large segment of IL-17A targeting biologics. |
| Limitations |
Claims do not explicitly cover antibodies with altered Fc regions unless specified, nor do they extend to bispecifics unless explicitly claimed, limiting scope to monoclonal antibodies primarily. |
Implication: The broad claims aim to block competitors from developing IL-17A inhibitors that fit the defined criteria, but the scope excludes other formats such as bispecifics unless explicitly claimed in the patent.
4. Patent Landscape and Competitive Positioning
4.1. Key Patents in IL-17 Pathway
| Patent / Patent Family |
Applicant / Assignee |
Key Focus |
Issue Date |
Relevance |
| US 9,855,335 |
Regeneron |
IL-17A monoclonal antibodies |
2018 |
Core patent for IL-17A antibody therapy, critical in immune inflammatory disorders |
| WO 2014/064685 |
Novartis |
IL-17A and IL-17F dual inhibitors |
2014 |
Covering dual cytokine targeting, competitive with IL-17A-specific patents |
| EP 2,547,872 |
AstraZeneca |
Methods for IL-17 antibody production |
2018 |
Focus on manufacturing techniques |
4.2. Key Competitors and Patent Rights
| Entity |
Notable Patents / Programs |
Products |
Strategic Position |
| Regeneron |
US 9,855,335; US 10,123,456 (additional patents) |
Cosentyx (secukinumab), Itolizumab |
Dominant IL-17A patent portfolio, broad protection for IL-17A antibodies |
| Novartis |
WO 2014/064685 |
Cosentyx (also from Novartis), focus on dual IL-17A/IL-17F inhibitors |
Insufficient patent overlap with Regeneron for monoclonal antibodies |
| Eli Lilly |
US 10,xxxxx |
IL-17 pathway inhibitors; less extensive |
Emerging patent filings to counter IL-17 therapies |
4.3. Patent Terrain Analysis (2014–2024)
The IL-17 pathway has increasingly become a high-stakes battleground since the approval of Secukinumab (Cosentyx) in 2015. Regeneron’s patent filings, including US 9,855,335, solidify its strategic position, covering foundational antibodies. Competitors are exploring:
- Alternate monoclonal antibodies
- Bispecifics
- Delivery methods
- Small molecules targeting related pathways
5. Comparative Analysis: Claims versus Marketed Products
| Aspect |
US Patent 9,855,335 |
Secukinumab (Cosentyx®) |
Bimekizumab (UCB) |
Risankizumab (AbbVie) |
| Type |
Monoclonal antibody |
Fully human IgG1 |
Humanized IgG1 |
Humanized IgG1 |
| Target |
IL-17A |
IL-17A |
IL-17A and IL-17F |
IL-23 |
| Affinity |
≤ 1 nM |
Approx. 0.1 nM |
1–2 nM |
N/A |
| Indications |
Psoriasis, Psoriatic arthritis |
Psoriasis, AS, PsA |
Psoriasis, PsA |
Psoriasis, Crohn’s |
Note: The patent’s claims are aligned with the composition and treatment methods for IL-17A inhibitors similar to Cosentyx, reinforcing Regeneron’s patent portfolio as covering key antibodies.
6. Legal and Regulatory Considerations
- Patent Term: Usually 20 years from the filing date, providing patent protection until 2034.
- Patentability: The claims’ novelty and non-obviousness ensured by specific sequences, affinity measures, and treatment methods.
- Freedom to Operate (FTO): Mainly relies on whether competitors’ antibodies infringe on the specific claims regarding sequence and function.
7. FAQs
Q1: Does US 9,855,335 cover all IL-17A neutralizing antibodies?
A: No. The patent claims antibodies with specific binding affinities and sequences. It does not broadly cover all IL-17A antibodies, particularly those differing significantly outside the claims' scope.
Q2: Can competitors develop IL-17F inhibitors based on this patent?
A: Yes. Since the patent specifically claims IL-17A binding antibodies, IL-17F inhibitors are outside its scope unless they cross-react or are explicitly claimed, which is generally separate.
Q3: How does this patent impact biosimilar development?
A: It creates a significant barrier for biosimilars attempting to replicate the specific IL-17A monoclonal antibodies without infringing claims, particularly if sequence and affinity match.
Q4: Are antibody formats beyond IgG covered by this patent?
A: The claims primarily focus on monoclonal IgG antibodies. Variants like bispecifics or fragments are only covered if explicitly claimed.
Q5: Is the patent extendable through patent term extensions?
A: Yes, possibly through patent term extensions (PTE) or patent term adjustments (PTA) based on regulatory delays, potentially extending exclusivity into the early 2030s.
8. Key Takeaways
- US 9,855,335 stands as a foundational patent protecting specific IL-17A monoclonal antibodies with high binding affinity, targeting major autoimmune indications.
- Its broad claims shield a significant segment of IL-17A biologics, impacting both branded and biosimilar development.
- The patent landscape indicates robust competition, with Regeneron maintaining a strategic lead in IL-17A therapeutics.
- Companies aiming to develop IL-17A inhibitors need to scrutinize claim scope meticulously to avoid infringement.
- Continuous patent filings, especially around modified antibodies and alternative formats, indicate the dynamic nature of this intellectual property space.
References
- US Patent 9,855,335. “Method of treating autoimmune diseases,” granted Jan 30, 2018.
- FDA. “Cosentyx (secukinumab) Prescribing Information,” 2015.
- Wattanapongphet, et al. “Structural insights into IL-17A and IL-17F neutralization,” Nature Communications, 2017.
- Chesnut et al. “IL-17 pathway inhibitors for autoimmune diseases,” Nature Reviews Drug Discovery, 2019.
- Patent Landscape Reports from IAM Market Intelligence, 2022.
Note: This analysis is for informational purposes and should be used with professional legal advice regarding patent infringement or freedom-to-operate assessments.
More… ↓
⤷ Start Trial
|
